- Home
- ELAB vs WGSWW Comparison
ELAB vs WGSWW Comparison
Compare ELAB & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- WGSWW
- Stock Information
- Founded
- ELAB 2020
- WGSWW N/A
- Country
- ELAB United States
- WGSWW United States
- Employees
- ELAB N/A
- WGSWW 1000
- Industry
- ELAB
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- ELAB
- WGSWW Technology
- Exchange
- ELAB Nasdaq
- WGSWW Nasdaq
- Market Cap
- ELAB N/A
- WGSWW N/A
- IPO Year
- ELAB 2023
- WGSWW 2020
- Fundamental
- Price
- ELAB $0.02
- WGSWW $0.19
- Analyst Decision
- ELAB
- WGSWW
- Analyst Count
- ELAB 0
- WGSWW 0
- Target Price
- ELAB N/A
- WGSWW N/A
- AVG Volume (30 Days)
- ELAB 283.9M
- WGSWW N/A
- Earning Date
- ELAB 11-14-2024
- WGSWW N/A
- Dividend Yield
- ELAB N/A
- WGSWW N/A
- EPS Growth
- ELAB N/A
- WGSWW N/A
- EPS
- ELAB N/A
- WGSWW N/A
- Revenue
- ELAB $2,446,161.00
- WGSWW N/A
- Revenue This Year
- ELAB N/A
- WGSWW N/A
- Revenue Next Year
- ELAB N/A
- WGSWW N/A
- P/E Ratio
- ELAB N/A
- WGSWW N/A
- Revenue Growth
- ELAB 112.17
- WGSWW N/A
- 52 Week Low
- ELAB $0.02
- WGSWW N/A
- 52 Week High
- ELAB $4.24
- WGSWW N/A
- Technical
- Relative Strength Index (RSI)
- ELAB 26.45
- WGSWW N/A
- Support Level
- ELAB $0.02
- WGSWW N/A
- Resistance Level
- ELAB $0.04
- WGSWW N/A
- Average True Range (ATR)
- ELAB 0.01
- WGSWW 0.00
- MACD
- ELAB 0.00
- WGSWW 0.00
- Stochastic Oscillator
- ELAB 6.85
- WGSWW 0.00
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.